Novo Nordisk's CEO to step down as competition weighs on Wegovy maker's share price

Core Viewpoint - Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down due to recent market challenges, with the company facing increased competition in the obesity drug market and disappointing trial results for next-generation treatments [1][3]. Group 1: Leadership Changes - Lars Fruergaard Jørgensen will remain in his position temporarily to ensure a smooth transition to new leadership, with a search for a replacement currently ongoing [2]. - Following the announcement of the CEO's departure, Novo Nordisk's shares fell by 1.8% [2]. Group 2: Market Challenges - Novo Nordisk's share price has been negatively impacted over the past year due to heightened competition in the obesity drug market [3]. - The company has also faced disappointing trial results for its next-generation treatments, contributing to the challenges it is currently experiencing [3]. Group 3: Company Strategy - Despite the leadership change and market challenges, Novo Nordisk's Chairman Helge Lund stated that the company's strategy remains unchanged, and the Board is confident in its current business plans and execution capabilities [3].